)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
biote
biote (BTMD) investor relations material
biote Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary4 Nov, 2026
Executive summary
Q3 revenue fell 9.6% YoY to $43.3M; procedure revenue declined while dietary supplements grew. Demand showed early signs of stabilization, but recovery is slower than anticipated.
Full-year 2026 guidance was maintained; priorities include clinic retention, practitioner engagement and sales productivity.
Financial highlights
Revenue was $43.3M versus $48.0M YoY; operating income was $2.5M versus $8.3M.
Net income was $0.6M versus $9.2M, and diluted EPS was $0.01 versus $0.22.
Adjusted EBITDA was $5.1M versus $12.9M YoY; adjusted EBITDA margin was 11.7% versus 26.9%.
SG&A rose 2.6% YoY to $26.8M but fell 20.8% QoQ, primarily on lower legal settlements and related expenses.
9M revenue was $132.5M versus $145.8M; net loss was $4.2M versus net income of $29.0M in 9M 2025.
Outlook and guidance
FY 2026 guidance remains revenue above $175M and adjusted EBITDA above $25M.
FY 2026 dietary supplements revenue is expected to grow at a mid- to high-single-digit rate from 2025.
Further sequential gross-margin improvement is anticipated as pellet supply shifts to internal manufacturing; management expects profiles similar to comparable periods last year as Asteria mix rises.
Normalized growth depends on new customer additions, same-store sales and attrition management; organizational and culture changes take time.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from biote
- Q2 2026 revenue fell 9.5% to $44.2M, with a net loss of $7.4M due to a major product recall.BTMD
Q2 2026 - Recall-driven supply issues led to lower Q1 revenue, but growth is expected to resume in H2 2026.BTMDQ1 2026
- Vote on two director nominees and auditor ratification at the May 2026 annual meeting.BTMDProxy filing
- Board recommends electing two directors and ratifying Deloitte as auditor at the annual meeting.BTMDProxy filing
- 2025 revenue and margins fell, but investments aim for renewed growth in H2 2026.BTMDQ4 2025
- Q3 revenue up 12.8% to $51.4M; 2024 guidance trimmed amid software and hurricane impacts.BTMDQ3 2024
- Q2 2024 saw procedure growth, strong margins, narrowed net loss, and reaffirmed 2024 guidance.BTMDQ2 2024
- Strong growth, tech-driven wellness expansion, and broad U.S. market opportunity highlighted.BTMDJefferies 2024 Global Healthcare Conference
- Q1 2025 net income reached $15.8M on 4.7% revenue growth and strong supplement sales.BTMDQ1 2025
biote
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Biote Corp. is a healthcare company focused on the medical practice-building business within the hormone optimization space. Founded in 2012 and headquartered in Irving, Texas, Biote Corp. specializes in offering a platform for Biote-certified practitioners. This platform is designed to help practitioners optimize their patients' hormone, vitamin, and mineral levels. Additionally, Biote Corp. enables the prescription of bioidentical hormone therapies and recommends dietary supplements. The company also markets Biote-branded dietary supplements and sterile pellet insertion kits, which are used alongside hormone optimization therapies for both male and female patients. The company is headquartered in Irving, Texas, and its shares are listed on the Nasdaq.